Tachy-Brady Syndrome in a Schizophrenic Patient: A Case Report.
adult cardiology
atrial arrhythmia
dual-chamber pacemaker
mental health issues
metoprolol
paranoid schizophrenia
sick sinus
tachy-brady syndrome
ventricular arrhythmia
Journal
Cureus
ISSN: 2168-8184
Titre abrégé: Cureus
Pays: United States
ID NLM: 101596737
Informations de publication
Date de publication:
Feb 2023
Feb 2023
Historique:
accepted:
27
02
2023
medline:
4
4
2023
entrez:
3
4
2023
pubmed:
4
4
2023
Statut:
epublish
Résumé
Tachy-brady syndrome is the result of sinus node dysfunction (SND), an electrocardiographic phenomenon caused by defective pacemaker functioning that leads to alternating arrhythmias. We present a case of a 73-year-old male with multiple mental health and medical comorbidities who was admitted to the inpatient floor for catatonia, paranoid delusions, refusal to eat, inability to cooperate with activities of daily life, and generalized weakness. Upon admission, a 12-lead electrocardiogram (ECG) showed an episode of atrial fibrillation with a ventricular rate of 64 beats per minute (bpm). During hospitalization, telemetry recorded a variety of arrhythmias such as ventricular bigeminy, atrial fibrillation, supraventricular tachycardia (SVT), multifocal atrial contractions, and sinus bradycardia. Each episode spontaneously reverted and the patient remained asymptomatic throughout these arrhythmic changes. These frequently fluctuating arrhythmias on resting ECG confirmed the diagnosis of tachycardia-bradycardia syndrome, also known as tachy-brady syndrome. Medical intervention, especially for cardiac arrhythmias, in patients with paranoid and catatonic schizophrenia can be challenging, as they might not share their symptoms. Additionally, certain psychotropic medications can also cause cardiac arrhythmias and must be carefully evaluated. The decision was made to start the patient on a beta-blocker and direct oral anticoagulation for reducing the risk of thromboembolic events. Due to an unsatisfactory response to drug therapy alone, the patient qualified as a candidate for definitive treatment with an implantable dual-chamber pacemaker. Our patient had a dual-chamber pacemaker implanted to prevent bradyarrhythmias and continued oral beta-blockers to prevent tachyarrhythmias.
Identifiants
pubmed: 37007363
doi: 10.7759/cureus.35557
pmc: PMC10063162
doi:
Types de publication
Case Reports
Langues
eng
Pagination
e35557Informations de copyright
Copyright © 2023, Knight et al.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
J Tehran Heart Cent. 2013 Oct 28;8(4):169-76
pubmed: 26005484
Circulation. 1996 Aug 1;94(3):578-83
pubmed: 8759105
Psychopharmacology (Berl). 1994 Feb;114(1):81-9
pubmed: 7846210
Int J Cardiol Heart Vasc. 2015 Dec 07;9:75-82
pubmed: 26839915
Biomedicines. 2023 Feb 07;11(2):
pubmed: 36831014
Arch Intern Med. 1997 Sep 22;157(17):2013-5
pubmed: 9308514
Am Heart J. 2000 Oct;140(4):541-51
pubmed: 11011325
Circulation. 2007 Apr 10;115(14):1921-32
pubmed: 17420362
Am Fam Physician. 2013 May 15;87(10):691-6
pubmed: 23939447
Front Neurol. 2015 Jun 24;6:139
pubmed: 26157417
Circulation. 2012 Aug 14;126(7):860-5
pubmed: 22891166
Circulation. 2019 Aug 20;140(8):e382-e482
pubmed: 30586772
Pharmacol Res. 2019 Aug;146:104274
pubmed: 31100336
Acad Emerg Med. 2017 Nov;24(11):1334-1348
pubmed: 28853232